1-2 of 2
Marisa Hill
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jeff P. Sharman, Talha Munir, Sebastian Grosicki, Lindsey Roeker, John M. Burke, Christine I Chen, Norbert Grzasko, George Follows, Zoltán Mátrai, Alessandro Sanna, Shuhua Yi, Ru Feng, Vu Minh Hua, Jadwiga Holodja, Wojciech Jurczak, Matthias Ritgen, Lu-Gui Qiu, Francesc Bosch, Catherine C. Coombs, Katherine Bao, Vishalkumar Patel, Bin Liu, Livia Compte, Ananya Guntur, Ying (Denise) Wang, Marisa Hill, Ching Ching Leow, Paolo Ghia, Paul M Barr
Journal: Blood
Blood (2024) 144 (Supplement 1): 886.
https://doi.org/10.1182/blood-2024-198147
Published: 2024
Journal Articles

BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Jeff P. Sharman, Wojciech Jurczak, Catherine C. Coombs, Marisa Hill, Denise Wang, Nora C. Ku, Ananya Guntur, Safi Shahda, Ching Ching Leow, Paolo Ghia, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 3736.
https://doi.org/10.1182/blood-2021-145926
Published: 2021